医药行业分析
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-19)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-18)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-17)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
- (2024-07-16)
天演药业将在2024年 ESMO 上公布其抗 CTLA-4 SAFEbody 安全抗体 ADG126 (muzastotug) 联合帕博利珠单抗治疗MSS CRC的最新数据
(2024-07-15)- (2024-07-15)